InMed Pharmaceuticals (INM) FCF Margin (2021 - 2025)
InMed Pharmaceuticals (INM) reported FCF Margin of 289.72% for Q4 2025, down 6465.0% on a YoY basis from 4.55% in Q4 2024, and down 101.86% quarter-over-quarter from 143.52% in Q3 2025.
InMed Pharmaceuticals (INM) FCF Margin (2021 - 2025) Analysis & Trends
InMed Pharmaceuticals has reported FCF Margin for 5 years, with the latest figure at 289.72% in Q4 2025.
- For the quarter ending Q4 2025, FCF Margin fell 6465.0% year-over-year to 289.72%; the trailing twelve-month figure through Dec 2025 stood at 164.69% (down 1377.0% YoY), and the FY2025 full-year result was 157.14%, down 500.0% from the prior year.
- FCF Margin for Q4 2025 stood at 289.72%, down from 143.52% in the prior quarter.
- The five-year high for FCF Margin was 29.85% in Q2 2023, with the low at 1728.88% in Q1 2022.
- Historically, FCF Margin has averaged 408.46% across 5 years, with a median of 164.96% in 2024.
- Annual changes were most pronounced in 2023 — FCF Margin jumped 156865 bps — and 2024, when it plunged 7605 bps.
- InMed Pharmaceuticals' FCF Margin stood at 1252.16% in 2021, then surged by 54 bps to 577.52% in 2022, then surged by 74 bps to 149.02% in 2023, then slumped by 51 bps to 225.07% in 2024, then slipped by 29 bps to 289.72% in 2025.
- The last three FCF Margin figures came in at 289.72% (Q4 2025), 143.52% (Q3 2025), and 136.31% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | -5.22% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 12.86% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 46.39% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 16.78% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | -2.77% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -429.96% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 32.62% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 13.24% |
| 10 | InMed Pharmaceuticals | 6.00 Mn | 756,271.05 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -289.72% |
| Sep 30, 2025 | -143.52% |
| Jun 30, 2025 | -136.31% |
| Mar 31, 2025 | -131.54% |
| Dec 31, 2024 | -225.07% |
| Sep 30, 2024 | -144.45% |
| Jun 30, 2024 | -80.21% |
| Mar 31, 2024 | -164.96% |
| Dec 31, 2023 | -149.02% |
| Sep 30, 2023 | -241.08% |
| Jun 30, 2023 | -29.85% |
| Mar 31, 2023 | -160.23% |
| Dec 31, 2022 | -577.52% |
| Sep 30, 2022 | -703.13% |
| Jun 30, 2022 | -786.24% |
| Mar 31, 2022 | -1,728.88% |
| Dec 31, 2021 | -1,252.16% |